Poly(ADP-Ribose) Polymerase Inhibitors in Prostate Cancer: Molecular Mechanisms, and Preclinical and Clinical Data

MLA

Ewa Iżycka-Świeszewska, et al. “Poly(ADP-Ribose) Polymerase Inhibitors in Prostate Cancer: Molecular Mechanisms, and Preclinical and Clinical Data.” Targeted Oncology, vol. 15, no. 6, Oct. 2020, pp. 709–22. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....694f3b4ba89c4eded9a269bb49a722e0&authtype=sso&custid=ns315887.

APA

Ewa Iżycka-Świeszewska, Lubomir Bodnar, & Dawid Sigorski. (2020). Poly(ADP-Ribose) Polymerase Inhibitors in Prostate Cancer: Molecular Mechanisms, and Preclinical and Clinical Data. Targeted Oncology, 15(6), 709–722.

Chicago

Ewa Iżycka-Świeszewska, Lubomir Bodnar, and Dawid Sigorski. 2020. “Poly(ADP-Ribose) Polymerase Inhibitors in Prostate Cancer: Molecular Mechanisms, and Preclinical and Clinical Data.” Targeted Oncology 15 (6): 709–22. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....694f3b4ba89c4eded9a269bb49a722e0&authtype=sso&custid=ns315887.